This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
G1 Therapeutics（GTHX）株式概要
G1セラピューティクス社は、商業段階のバイオ医薬品会社で、米国においてがん患者を対象とした低分子治療薬の発見、開発、商業化に従事している。 詳細
GTHX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
G1 Therapeutics, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$7.15 |
| 52週高値 | US$7.19 |
| 52週安値 | US$1.08 |
| ベータ | 1.68 |
| 1ヶ月の変化 | 0.85% |
| 3ヶ月変化 | 182.61% |
| 1年変化 | 433.58% |
| 3年間の変化 | -52.55% |
| 5年間の変化 | -78.80% |
| IPOからの変化 | -52.33% |
最新ニュース
Recent updates
分析記事 • Jul 26
There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise
Those holding G1 Therapeutics, Inc. ( NASDAQ:GTHX ) shares would be relieved that the share price has rebounded 80% in...Seeking Alpha • Jun 24
G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty
Summary G1 Therapeutics, Inc. faces a setback as a trial for triple-negative breast cancer fails to improve survival, leading to a significant market selloff. The company's main drug, trilaciclib, shows potential for reducing severe neutropenia but fails to meet the primary endpoint in the breast cancer trial. Despite financial challenges and market pessimism, G1 Therapeutics maintains an approved drug with growing sales and potential in niche markets like small cell lung cancer. Read the full article on Seeking Alpha分析記事 • Jun 07
Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why
Key Insights G1 Therapeutics to hold its Annual General Meeting on 13th of June CEO Jack Bailey's total compensation...分析記事 • May 28
Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 2.5x G1 Therapeutics, Inc. ( NASDAQ:GTHX ) is definitely a...分析記事 • May 04
G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Shareholders of G1 Therapeutics, Inc. ( NASDAQ:GTHX ) will be pleased this week, given that the stock price is up 13...Seeking Alpha • Mar 22
Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape
Summary G1 Therapeutics is a biopharmaceutical company that develops and commercializes advanced oncology treatments. Its flagship product, Cosela, is an FDA-approved drug for reducing chemotherapy side effects in patients with Extensive-Stage Small Cell Lung Cancer. The company's research pipeline includes exploring new indications for Trilaciclib in breast and bladder cancer, reporting a 29% increase in Cosela's net revenues in Q4 2023. Trilaciclib's further successful development and commercialization are crucial for GTHX's valuation and future revenue streams, and early trials suggest that it is effective. Despite cash burn and dilution concerns, I rate GTHX a speculative "buy" due to its promising revenue growth and product pipeline. Read the full article on Seeking Alpha分析記事 • Feb 27
Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge
G1 Therapeutics, Inc. ( NASDAQ:GTHX ) shares have retraced a considerable 44% in the last month, reversing a fair...分析記事 • Feb 06
Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Jan 04
G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry
Despite an already strong run, G1 Therapeutics, Inc. ( NASDAQ:GTHX ) shares have been powering on, with a gain of 61...分析記事 • Jun 08
Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues
With a price-to-sales (or "P/S") ratio of 2.6x G1 Therapeutics, Inc. ( NASDAQ:GTHX ) may be sending very bullish...分析記事 • May 08
New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)
Celebrations may be in order for G1 Therapeutics, Inc. ( NASDAQ:GTHX ) shareholders, with the analysts delivering a...分析記事 • Nov 04
The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts
The analysts covering G1 Therapeutics, Inc. ( NASDAQ:GTHX ) delivered a dose of negativity to shareholders today, by...Seeking Alpha • Oct 20
G1 Therapeutics: Catalysts Stacking
Summary Though no longer having Boehringer as its launch partner, G1 Therapeutics, Inc. posted good sales traction for Cosela. There are several big data releases going into the year-end and next year that can significantly move the needle on this stock. If data for the first-line label expansion proved positive, Cosela would likely become a blockbuster. G1 Such a study indicates that the greatest investment reward comes to those who by good luck or good sense find the occasional company that over the years can grow in sales and profits far more than industry as a whole. - Phillip Fisher (Warren Buffett's mentor) In biotech investing, you want to pick a company that has multiple catalysts like a data release stacked in close sessions. After all, if one data release flops there would be additional clinical reporting to galvanize the shares price. Despite that its marketing partner Boehringer left, I still like G1 Therapeutics (GTHX) because of the substantial unlocked value in Cosela. Going into yearend and next year, there is a flurry of catalysts that can substantially improve the investment prospects of this company. In this research, I'll feature a fundamental analysis of G1 and share with you my expectation of this intriguing equity. StockCharts Figure 1: G1 Therapeutic Chart About The Company As usual, I'll present a brief corporate overview for new investors. If you're familiar with the firm, I suggest that you skip to the next section. Operating out of the Research Triangle Park, North Carolina, G1 Therapeutics is a commercial-stage company focusing on the innovation and commercialization of next-generation medicines to fulfill the unmet needs in cancers. As the "crown jewel" of this pipeline, Cosela is already FDA-approved for the treatment of chemotherapy-induced myelosuppression in adult patients with metastatic small-cell lung cancer (mSCLC). In expanding its label, G1 is investigating Cosela as monotherapy and in combination with other drugs for various solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Figure 2: G1 Therapeutics chart Mechanism Of Action (MOA) Of Cosela Shifting gears, let us walk through the various fundamental developments pertaining to Cosela/G1. Whenever appropriate, I'd present to you the research format that illustrates the MOA, Disease Context (i.e., DC), and supporting data. That way, you can better appreciate your data forecasting. More importantly, it'll give you more context in "reading the tea leaves" to stay ahead of the market. On this front, you can see that Cosela's MOA is crucial in the treatment of a vast number of cancer indications. Notably, chemotherapy kills both the cancer cells as well as normal cells (including cells of the immune system like the T-cells). But in order for chemotherapy to kill these cells, the cell has to be able to move forward in its "cell cycle." That is to say, those cells have to advance from immature precursors to their matured forms. As a transient CDK46 inhibitor, Cosela "temporarily" halts the cell cycle of key cells needed to combat cancers. Consequently, Cosela can theoretically protect various (i.e., myeloid and lymphoid) cells from damage caused by chemotherapy. With the aforesaid key cells being protected, Cosela ultimately boosts immune system functioning. Notably, this MOA is logical to me, but there is still some "gray area" in my thinking. Simply put, it's not as clear-cut as other MOAs. G1 Figure 3: Cosela mechanism of action Disease Context For Various Cancers As you can imagine, the MOA of Cosela (i.e., boosting immune cells) is very important for the treatment of cancers. After all, tumor cells exert "suppressive effects" on the immune system. As you can appreciate, the MOA of Cosela - in protecting immune/blood cells and strengthening the immune function - "more or less fits" into the cancer Disease Context like puzzle pieces. As such, it explicates and foretells upcoming strong clinical data results. The solid proof in the pudding of Cosela's efficacy is that it is already approved and launched for the treatment of myelosuppression associated with chemotherapy treatment for lung cancer. Upcoming Catalysts In 4Q2022 As catalysts can move the needle on your stock, you want to check up on the vast number of upcoming data reports. Beyond the potential share price appreciation, those catalysts can also ramp up Cosela's sales. Toward year-end, there is an upcoming data release for the Phase 2 trial that assesses Cosela in 24 patients suffering from early-stage triple-negative breast cancer (i.e., TNBC). This study further explores the MOA of Cosela. The study's primary endpoint is the immune-based MOA. That includes Cosela's impact on CD8+ T-cells (i.e., killer T-cells) and regulatory T cells (i.e, T-regs) in the tumor's environment. A key secondary endpoint is the pathological complete response rate (i.e., PCR). That aside, there are two Phase 2 combo investigations poised to release their data soon. The first is a combo study with an antibody-drug conjugate (i.e, ADC) known as Trodelvy for advanced TNBC. Here is where it gets interesting with the second study, i.e., the Phase 2 (PRESERVE 3) trial. Notably, PRESERVE 3 assesses Cosela with chemotherapy and an immune checkpoint inhibitor dubbed Avelumab in 92 patients with bladder cancer. With Enrollment already completed, G1 would release the initial data by yearend. Next year, there are more data releases (i.e., progression-free survival) for PRESERVE 3. Now, PRESERVE 3 is very important because it can position Cosela+Trodelvy to become the first line (i.e, 1L) treatment for bladder cancer. Over the decades, I have noticed that 1L therapeutics have the best chances of becoming blockbusters. G1 Figure 4: PRESERVE 2 trial Commercialization Progress In the latest earnings report, G1 reported $8.7M in Cosela sales. While that isn't much, it's significant for a small company like G1. Had Boehringer still been on board, you can bet that sales would have been much higher. Interestingly, G1 noted in the earnings conference call that Cosela is now approved in China. In connection with the milestone achieved, the China partner (Simcere) will pay G1 $13M as part of the total $156M to be earned. I like that development because G1 can leverage a partner like Simcere who knows the China market. With Simcere, you can expect a stronger revenue ramp-up. Commenting on the recent development, the CEO (Jack Bailey) remarked: The second quarter of 2022 was a period of continued momentum across the G1 organization toward our mission of improving the lives of those impacted with cancer. For the first time, our sales team was in full control of Cosela, interacting with prescribers and driving usage and uptake. Thanks to the quality of these engagements, we experienced nearly 60 percent vial volume growth quarter over quarter - our highest quarterly growth rate since the initial launch period. In addition, our clinical team continued to execute on each of our ongoing clinical trials, including achieving important enrollment milestones in our Phase 3 trial of trilaciclib in patients with colorectal cancer and in our Phase 2 bladder cancer and mechanism of action trials. Financial Assessment Just as you would get an annual physical for your well-being, it's important to check the financial health of your stock. For instance, your health is affected by "blood flow" as your stock's viability is dependent on the "cash flow." With that in mind, you should assess the 2Q2022 earnings report for the period that ended on June 30. As follows, G1 procured $10.5M in total revenues, compared to only $6.6M for the same period a year prior. Of the revenues, Cosela's sales for the respective periods registered at $8.7M and $2.5M. Therefore, product sales increased by 248% year-over-year (YOY).Seeking Alpha • Sep 29
G1 Therapeutics: Building A Franchise
Summary Today, we put G1 Therapeutics, Inc. in the spotlight. The company's main asset is COSELA, a small-molecule, short-acting, inhibitor of cyclin-dependent kinases 4 and 6. COSELA has been approved for one indication and is in numerous studies targeting other oncology afflictions. So, what's next for G1 Therapeutics as it tries to build out a potential blockbuster franchise? An investment analysis follows in the paragraphs below. "Humility is nothing but artfully disguised arrogance." Gourav Mohanty Today, we take a look at a small developmental concern that has seen a nice rise in its stock over the past couple of months despite a dismal market backdrop. Can the rally in the shares continue? An analysis follows below. Seeking Alpha Company Overview: G1 Therapeutics, Inc. (GTHX) is based in North Carolina. This clinical-stage biopharmaceutical company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. Currently, the stock trades just below $13.00 a share and sports an approximate market capitalization of $520 million. September Company Presentation The company's main asset is a drug named trilaciclib which goes by the brand name COSELA. The product is a small-molecule, short-acting, inhibitor of cyclin-dependent kinases 4 and 6. COSELA is used to reduce the risk of blood/bone marrow problems (such as low red/white blood cells and platelets) caused by chemotherapy. It is also tumor-agnostic. September Company Presentation This compound is already FDA approved to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum etoposide continue regimen or a topotecan containing regimen for extensive stage small cell lung cancer or ES-SCL in the first quarter of 2021. This is a relatively small indication, and COSELA only did $8.7 million of net product revenue in the second quarter of this year. Vials sold did increase 60% on a year-over-year basis, it should be noted. COSELA was recently approved in China. This entitled G1 Therapeutics to $13 million in the form of a milestone payment and potentially $156 million in additional milestone payouts from its marketing partner Simcere in China as well as double-digit royalties on net product revenues. September Company Presentation However, leadership envisions an entire pipeline based on this asset. Trilaciclib is being evaluated across a range of tumor types and chemotherapy regimens to assess its potential myeloprotection, antitumor efficacy and safety in combination with chemotherapy and other agents. September Company Presentation As you can see above, the company has a couple of registrational studies in progress as well as several Phase 2 trials for various new indications for COSELA. The first registrational trial is targeting metastatic colorectal cancer or mCRC and called PRESERVE 1. This is a global multi-center, randomized placebo-controlled, line extension pivotal 326-person Phase 3 trial of trilaciclib metastatic CRC receiving first-line trilaciclib or placebo administered prior to FOLFOXIRI (a combination of fluorouracil (5-FU), folinic acid, oxaliplatin and irinotecan) and bevacizumab. September Company Presentation The population impacted by mCRC is potentially three times bigger than that SCLC for COSELA. Colorectal cancer is the second-largest cause of cancer death in the United States, with some 150,000 Americans diagnosed with this disease. Most currently receive 5-FU based chemotherapy regimens. September Company Presentation Enrollment for PRESERVE-1 was completed in the second quarter. Initial results from this study, which include those from the primary endpoint in the first quarter of 2023. This trial was pushed back by the invasion of Ukraine. This study was overenrolled to compensate for loss of patient data in Ukraine due to the ongoing conflict. Initial Data from a Pivotal Phase 3 Trial of Trilaciclib in Triple Negative Breast Cancer or mTNBC is due out in the second half of 2023. This 170-person study 'PRESERVE 2' target patients with PD-L1 positive and negative metastatic TNBC receiving first-line gemcitabine and carboplatin. An interim overall survival analysis should be conducted by a data monitoring committee in the second half of 2023. If that data meets the criteria, the trial will stop. If not, it will go onto final analysis. September Company Presentation A Phase II trial for this indication saw robust statistically significant improvements in the most clinically meaningful endpoint of overall survival in patients receiving trilaciclib compared to patients in the control group, with hazard ratios of 0.31 and 0.4 in the two trilaciclib groups. September Company Presentation Initial readouts from three Phase 2 trials for additional indications should be out by the end of this year. September Company Presentation Analyst Commentary & Balance Sheet: Two weeks ago, Wedbush ($25 price target, up from $20 previously), Needham ($32 price target) and H.C. Wainwright ($67 price target) all reissued Buy ratings on the stock. On August 3rd, JPMorgan Chase maintained its Sell rating on the stock with a $14 price target. Insiders were small sellers in the stock through the first half of the year. However, two insiders have taken advantage of the recent pop in the stock to dispose of nearly $1.6 million worth of shares in aggregate over the past six weeks. Just over 10% of the overall float in the shares is currently held short. The company ended the second quarter of this year with just under $145 million in cash and marketable securities on its balance sheet against just north of $75 million in long-term debt. This does not include the $13 million milestone payment from Simcere. The company posted a loss of $39.4 million in the second quarter. Management has guided it believes funding in place is sufficient to fund activities planned into 2024. Verdict: G1 Therapeutics' future looks promising as COSELA or trilaciclib is already approved for one indication with the potential for approval for several larger indications in the years ahead. Readouts from five different trials (Two registrational and three Phase II) should also be out over the next year or so.分析記事 • Aug 04
Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)
Celebrations may be in order for G1 Therapeutics, Inc. ( NASDAQ:GTHX ) shareholders, with the analysts delivering a...Seeking Alpha • Aug 02
G1 Therapeutics Q2 2022 Earnings Preview
G1 Therapeutics (NASDAQ:GTHX) is scheduled to announce Q2 earnings results on Wednesday, August 3rd, before market open. The consensus EPS Estimate is -$1.01 (-7.4% Y/Y) and the consensus Revenue Estimate is $8.87M (+34.4% Y/Y). Over the last 2 years, GTHX has beaten EPS estimates 63% of the time and has beaten revenue estimates 75% of the time. Over the last 3 months, EPS estimates have seen 0 upward revisions and 5 downward. Revenue estimates have seen 3 upward revisions and 3 downward.Seeking Alpha • Jul 22
G1 Therapeutics: Take Advantage Of The November Data
GTHX will topline the mCRC phase 3 trial in November. This will help expand its label and increase revenues. Although up considerably, GTHX stock is still below its earlier highs. G1 Therapeutics (GTHX) is up 50% since my April write-up. The upward movement started from mid-June, and when I am looking for reasons, I see this - the last patient has been randomized in the Phase 3 clinical trial of trilaciclib for patients with metastatic colorectal cancer (mCRC) receiving chemotherapy (PRESERVE 1). That means, the trial is now fully enrolled. In order to understand why this is important, go through my earlier articles quickly. While trilaciclib is already FDA approved to mitigate chemotherapy-induced myelosuppression in adult patients with small cell lung cancer, the stock has been struggling to make money, and mCRC and TNBC are its big indications. The stock was down for a long time after trilaciclib's approval because the drug wasn't making enough money for the company. The principal reason for this was GTHX was not able to find the right marketing partner for its drug, and was thus unable to access the big accounts despite getting reimbursement with a permanent J-code. However, SCLC is a much smaller market than either mCRC or TNBC, and being tumor-agnostic, trilaciclib is eventually going to get approved in these indications. The PRESERVE-1 trial will topline in November this year, while TNBC will be 2-3 years later. The excitement surrounding GTHX is because of mCRC data readout. Here's what PRESERVE-1 looks like: PRESERVE 1 is a global multi-center, randomized placebo-controlled, line extension pivotal Phase 3 trial of trilaciclib in 326 patients with metastatic CRC receiving first line trilaciclib or placebo administered prior to FOLFOXIRI (a combination of fluorouracil (5-FU), folinic acid, oxaliplatin and irinotecan) and bevacizumab. The regimen is given for two consecutive days of every 14-day cycle. Patients are receiving trilaciclib or placebo administered prior to their chemotherapy for a maximum of 12 cycles of induction followed by maintenance therapy. Treatment is administered until disease progression. There are 150,000 US patients with Colorectal cancer, most of whom receive 5-FU based chemotherapy regimen. CRC is the second most common cause of cancer death, representing about 12-14% of all cases. Around 25% of patients present with metastasis at diagnosis, which can eventually go up to 50%. Looking at the numbers, mCRC is about thrice the target market compared to SCLC, which is one reason for recent excitement surrounding trilaciclib. The entire CRC market is estimated to be around $20bn, while SCLC is about a third of that. Most mCRC patients receive a combination of leucovorin, fluorouracil, oxaliplatin, and irinotecan in the first-line setting, often in combination with a monoclonal antibody targeting the epidermal growth factor receptor (EGFR) or vascular endothelial growth factor (VEGF) pathways. While treatment quality has vastly improved over the years, it has also led to increased toxicity, specifically from induced myelosuppression and its resultant problems. This has caused the chemo regimen to be used mainly in younger patients with fewer comorbidities. Trilaciclib is intended to reduce myelosuppression in a lineage-agnostic manner, meaning it is useful whether you have developed neutropenia, anemia or thrombocytopenia. There are no specific phase 2 trials in mCRC available. However: Data from 3 randomized, placebo-controlled, phase 2 clinical trials showed that administering trilaciclib prior to chemotherapy reduced the incidence of chemotherapy-induced myelosuppression, and reduced the need for supportive care interventions and chemotherapy dose reductions/delays • Additionally, in a randomized phase 2 trial in patients with metastatic triple-negative breast cancer, administering trilaciclib prior to gemcitabine plus carboplatin significantly improved OS compared with chemotherapy alone, potentially through protection and direct activation of immune function株主還元
| GTHX | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | 0.3% | 1.2% | 1.1% |
| 1Y | 433.6% | 34.6% | 28.7% |
業界別リターン: GTHX過去 1 年間で34.6 % の収益を上げたUS Biotechs業界を上回りました。
リターン対市場: GTHX過去 1 年間で28.7 % の収益を上げたUS市場を上回りました。
価格変動
| GTHX volatility | |
|---|---|
| GTHX Average Weekly Movement | 19.9% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: GTHXの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: GTHXの weekly volatility ( 20% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2008 | 100 | Jack Bailey | www.g1therapeutics.com |
G1 Therapeutics, Inc.は、商業段階のバイオ医薬品企業であり、米国において癌患者の治療のための低分子治療薬の発見、開発、商業化に従事している。同社は、プラチナ製剤／エトポシド製剤を含むレジメンまたはトポテカン製剤を含むレジメンで治療を受けた広範なステージの小細胞肺癌の成人患者において、化学療法誘発性骨髄抑制の発生を減少させるCOSELAを提供している。また、トリラシクリブの開発を進めており、1L転移性トリプルネガティブ乳がん（mTNBC）を対象とした第3相臨床試験、mTNBCを対象とした抗体薬物複合体試験としての第2相臨床試験、ネオアジュバントTNBCおよび1L膀胱がんを対象とした第2相臨床試験を完了した。また、ジェノア・バイオファーマ社とは、ヒトの様々な適応症を対象とした経口剤形によるレロシクリブの開発・商業化に関するライセンス契約を、インサイクリックス社とは、ヒトおよび動物用のあらゆる適応症を対象としたCDK2阻害剤の開発・商業化に関するライセンス契約を、シムセア社とは、あらゆる適応症を対象としたトリラシクリブの開発・商業化に関するライセンス契約を締結している。G1セラピューティクス社は2008年に設立され、ノースカロライナ州リサーチ・トライアングル・パークに本社を置いている。
G1 Therapeutics, Inc. 基礎のまとめ
| GTHX 基礎統計学 | |
|---|---|
| 時価総額 | US$378.17m |
| 収益（TTM） | -US$44.77m |
| 売上高(TTM) | US$58.20m |
6.5x
P/Sレシオ-8.4x
PER（株価収益率GTHX は割高か？
公正価値と評価分析を参照収益と収入
| GTHX 損益計算書（TTM） | |
|---|---|
| 収益 | US$58.20m |
| 売上原価 | US$6.14m |
| 売上総利益 | US$52.05m |
| その他の費用 | US$96.82m |
| 収益 | -US$44.77m |
直近の収益報告
Jun 30, 2024
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.85 |
| グロス・マージン | 89.44% |
| 純利益率 | -76.93% |
| 有利子負債／自己資本比率 | 180.2% |
GTHX の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2024/09/18 13:27 |
| 終値 | 2024/09/18 00:00 |
| 収益 | 2024/06/30 |
| 年間収益 | 2023/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
G1 Therapeutics, Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8
| アナリスト | 機関 |
|---|---|
| Harshita Polishetty | B. Riley Securities, Inc. |
| Dane Leone | BTIG |
| Charles Butler | D. Boral Capital LLC. |